Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 16/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29562794 | 1.00 | TYK2 (0.45) | TYK2JAK2ALOX5JAK1 | |
| SCHEMBL21329691 | 1.00 | TYK2 (0.45) | TYK2JAK2ALOX5JAK1 | |
| SCHEMBL21329689 | 1.00 | TYK2 (0.45) | TYK2JAK2ALOX5JAK1 | |
| SCHEMBL29562754 | 1.00 | TYK2 (0.45) | TYK2JAK2ALOX5JAK1 | |
| SCHEMBL29562549 | 0.85 | TYK2 (0.35) | TYK2JAK2ALOX5 | |
| SCHEMBL29563620 | 0.84 | TYK2 (0.38) | TYK2JAK2ALOX5JAK1 | |
| SCHEMBL29562736 | 0.84 | TYK2 (0.38) | TYK2JAK2ALOX5JAK1 | |
| SCHEMBL29562567 | 0.84 | TYK2 (0.38) | TYK2JAK2ALOX5JAK1 | |
| SCHEMBL31161395 | 0.84 | TYK2 (0.36) | TYK2JAK2ALOX5JAK1 | |
| SCHEMBL24377774 | 0.83 | TYK2 (0.47) | TYK2JAK2ALOX5JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2022109580-A1 | INHIBITION OF TYK2 DEPENDENT SIGNALING PATHWAYS | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-27 | — | — | WO | disclosed |
| US-20200255423-A1 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | ABBVIE INC (US) | 2020-08-13 | — | — | US | disclosed |
| WO-2019178079-A9 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | ABBVIE INC. (US) | 2019-12-12 | — | — | WO | disclosed |
| WO-2019178079-A1 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | ABBVIE INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| EP-3539966-A1 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | AbbVie Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-3539966-A1 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | AbbVie Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20190276450-A1 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | ABBVIE INC. | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | TYK2 1/4885JAK2 24/4885ALOX5 3291/4885 |
| US-20190276450-A1 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | PTK2B, ABL1, BTK | TYK2 36/4885JAK2 8/4885ALOX5 4798/4885 |
| US-20200255423-A1 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | PTK2B, ABL1, BTK | TYK2 36/4885JAK2 8/4885ALOX5 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.